Clinical Trials Browser

NIH × Lung Neoplasms × AZD 6244 × Clear all

NCT01229150 2017-05-23

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Phase 2 Completed

89 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms